Pharma Foods International Co., Ltd.
Financial Results for the Third Quarter of the Fiscal Year Ending July 2026 (Japan GAAP, Consolidated)
Sales revenue of 48,555 million yen, operating loss of 1,430 million yen, net income attributable to owners of the parent company of -1,061 million yen. Expecting a full-year black ink turning, continuing growth investments. Emphasizing progress on Medium-Term Plan 2026 and securing funding for growth investments.
Key Figures
- Sales: 48,555 million yen
- Operating income: -1,430 million yen
- Net income attributable to owners of the parent: -1,061 million yen
AI要約
Overview of Results
For the cumulative third quarter of the current fiscal year, net sales increased YoY and gross profit also rose, but operating loss widened due to continued growth in selling, general and administrative expenses and advertising/marketing investments. For the full year, a net income of the current period turning to black is planned, with a strategy to achieve profit in the second half. From the perspective of securing funds for growth investments, interest-bearing debt has increased, but improvement is expected by the year-end.
Outlook and Strategy
Taking into account progress on the Medium-Term Management Plan 2026, continuing growth investments in BtoC centered on the Newmo series. While maintaining gross margin on high-value-added products, link the effect of increased advertising expenses to sales growth. Financially, pursue improvement in return on capital and strengthening of the financial foundation, with a plan to improve ROE/cost of capital.
PharmaFoods Co., Ltd.
Company overview · Stock price · Financial data · All IR
